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Background: Intravenous tranexamic acid (TXA) reduces bleeding deaths after injury and childbirth. It is most effective
when given early. In many countries, pre-hospital care is provided by people who cannot give i.v. injections. We
examined the pharmacokinetics of intramuscular TXA in bleeding trauma patients.
Methods: We conducted an open-label pharmacokinetic study in two UK hospitals. Thirty bleeding trauma patients
received a loading dose of TXA 1 g i.v., as per guidelines. The second TXA dose was given as two 5 ml (0$5 g each) i.m.
injections. We collected blood at intervals and monitored injection sites. We measured TXA concentrations using liquid
chromatography coupled to mass spectrometry. We assessed the concentration time course using non-linear mixed-
effect models with age, sex, ethnicity, body weight, type of injury, signs of shock, and glomerular filtration rate as
possible covariates.
Results: Intramuscular TXA was well tolerated with only mild injection site reactions. A two-compartment open model
with first-order absorption and elimination best described the data. For a 70-kg patient, aged 44 yr without signs of shock,
the population estimates were 1.94 h1 for i.m. absorption constant, 0.77 for i.m. bioavailability, 7.1 L h1 for elimination
clearance, 11.7 L h1 for inter-compartmental clearance, 16.1 L volume of central compartment, and 9.4 L volume of the
peripheral compartment. The time to reach therapeutic concentrations (5 or 10 mg L1) after a single intramuscular TXA
1 g injection are 4 or 11 min, with the time above these concentrations being 10 or 5.6 h, respectively.
Conclusions: In bleeding trauma patients, intramuscular TXA is well tolerated and rapidly absorbed.
Clinical trial registration: 2019-000898-23 (EudraCT); NCT03875937 (ClinicalTrials.gov).
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Editor’s key points
 Early administration of i.v. tranexamic acid can help
prevent haemorrhage-related deaths in trauma and
childbirth.
 This prospective, open-label study examined the
pharmacokinetics of i.m. tranexamic acid injections in
bleeding trauma patients.
 Tranexamic acid was rapidly absorbed, even when
hypovolaemic shock was present, and reached thera-
peutic plasma concentrations within 15 min.
 Use of the i.m. route may facilitate and increase use of
this potentially life-saving drug in trauma and other
bleeding patients, especially in low- and middle-
income countries.
2 - Grassin-Delyle et al.Intravenous tranexamic acid (TXA) reduces bleeding deaths
after injury and childbirth.1,2 When given within an hour of
bleeding onset, TXA reduces haemorrhage deaths by one-
third.3 Thereafter, the survival benefit decreases by about 10%
for every 15 min treatment delay until around 3 h after which
there is no benefit.3 In high-income countries, paramedics give
an i.v. injection of TXA at the scene of the injury or in the
ambulance.4 However, securing i.v. access can be difficult,
particularly in trapped patients. Rapid TXA treatment is
particularly challenging in low- and middle-income countries
that lack formal pre-hospital care systems.5,6 In the absence of
highly trained staff, bystanders or police officers provide basic
first aid.7,8 Patients are usually taken to the nearest primary
healthcare centre, often in private vehicles or rudimentary
ambulances, where they receive basic care (tetanus toxoid,
suturing, and X-rays) before transfer to a tertiary hospital.9 As
a result, few patients receive TXA within 3 h of injury and
hardly any within the first hour.10 If TXA could be given
intramuscularly, it could be given by trained first responders,
police officers, ambulance drivers, and primary care nurses
with important reductions in time to treatment.
Intramuscular TXAmight also increase access to treatment
for women with postpartum haemorrhage (PPH). In low- and
middle-income countries, about 40% of women deliver at
home. Although community health workers are often present,
most cannot give i.v. drugs. Transport to hospital can take
hours, and many women exsanguinate on the way. Although
i.v. TXA is the treatment of choice, this is not an option for tens
of thousands of women. Finding alternative routes to give TXA
in women with PPH is a WHO research priority.11
Studies in healthy volunteers show that therapeutic TXA
concentrations (5e10 mg L1) are reached within 30 min after
i.m. injection of TXA 500 mg.12,13 If absorption is as rapid in
trauma patients, then the i.m. route could be an alternative to
i.v. use. The main uncertainty is the impact of bleeding on
muscle absorption of TXA. Acute blood loss leads to
compensatory cardiovascular changes that maintain blood
flow to vital organs at the expense of peripheral tissues. Skin
and skeletal muscle are main targets for this response with
significant reductions in muscle blood flow.14 This could
reduce the absorption of TXA from muscle. To resolve this
uncertainty, we examined the pharmacokinetics of i.m. TXA
in bleeding trauma patients.Methods
We conducted a prospective, open-label pharmacokinetic
study in the emergency departments of two London hospitals.
Adult (patient appears to be at least 16 yr old) trauma patients
who had received an i.v. TXA 1 g loading dose, either pre-
hospital or in-hospital, were eligible if a second TXA dose
was indicated. These patients received the second TXA 1 g
dose by i.m. injection at least 90 min after the first injection.
The i.m. dose was given as two 5 ml (0.5 g each) injections into
the thigh (rectus femoris or vastus lateralis), gluteal, or deltoid
muscles, depending on the clinical situation (e.g. considering
the type of injury). The dose was divided to reduce the volume
injected into each muscle (5 ml is considered the upper limit).
The i.m. injections were given into non-injured muscles using
the Z-trackmethod to reduce TXA leakage.15 Trial participants
had experienced a sudden life-threatening injury with signif-
icant bleeding. If appropriate, the treating doctor explained the
trial procedures, and if the patient was competent, written
consent was sought. If capacity was impaired and a personal
or professional representative was available, then consent
was sought from the representative. If neither was able to
provide consent, then consentwaswaived and the patient was
told about the trial and consent obtained for ongoing data
collection as soon as possible. The Health Research Authority
and LondoneChelsea Research Ethics Committee (19/LO/0945)
approved the trial.
We collected baseline data on age, sex, height, weight,
ethnic origin (because it affects glomerular filtration rate
[GFR]), time of injury and i.v. TXA administration, blood
pressure, temperature, heart, ventilatory frequency, and the
presence or absence of signs of shock (a clinical judgement
made by the treating doctor). We collected blood test results
(base excess, lactate, and creatinine) to assess shock and renal
function. All physiological parameters were collected imme-
diately before the i.m. TXA injection.
The blood sampling schedule was as follows: 10 min after
i.v. injection; immediately before the i.m. injection; and 15
min, 45 min, 90 min, 3 h, 6 h, and 10 h afterwards. Because
patient care had priority over sampling, we expected sampling
times to vary from those shown. If we could not obtain a
sample at the scheduled time, we collected blood as soon as
possible and recorded the collection time. We collected 2 ml of
blood in tubes without anticoagulant (BD Vacutainer® EST™
Blood Collection Tubes, Becton, Dickinson UK Limited). We
took blood from a cannula to avoid multiple venepunctures.
We centrifuged samples for 10 min at 1500 g and transferred
the serum to a storage tube, which was stored at e80C before
shipment to the laboratory. Each time blood was taken, we
inspected the i.m. injection sites for reactions. We continued
to inspect once daily for 7 days or until prior hospital
discharge. We also recorded blood pressure, temperature,
heart, and ventilatory frequency. We collected data on treat-
ments that may influence TXA concentrations (e.g. blood
products and i.v. fluids) from the time of the i.m. injection to
the time of the last sample. Adverse events were recorded for
up to 7 days. We measured TXA concentrations using liquid
chromatography coupled to mass spectrometry. The method
is linear in the range 1.0e1000.0 mg ml1, accuracy is between
88.4% and 96.6%, and precision <3.0%.16,17
Table 1 Patient characteristics and treatments. Continuous
data are presented as mean (standard deviation). Glomerular
filtration rate calculated using the Modification of Diet in
Renal Disease (MDRD) study group equation. TXA, tranexamic
acid.
Parameter Number of
patients
Number of patients, n 30
Type of injury (blunt/penetrating), n 24/6
Male/female, n 26/4
Age (yr) 50 (23)
Body weight (kg) 78 (14)
Height (cm) 174 (9)
BMI (kg m2) 26 (4)
Ethnicity (Asian/Black/mixed/White) 3/2/1/24
Serum creatinine (mM) 109 (28)
MDRD glomerular filtration rate (ml min1
[1.73 m2]1)
72 (20)
Clinical signs of shock (yes/no), n 18/12
Site of injection (both i.m. doses into rectus
femoris/vastus lateralis/gluteal/deltoid/
different muscles)
2/8/1/17/2
Time between injury and i.v. TXA dose (h) 1.1 (0.7)
Time between i.v. and i.m. TXA doses (h) 1.8 (0.3)
Systolic blood pressure (mm Hg) 114 (27)
Blood gas lactate (mM) 4 (4)
Blood product transfusion (yes/no) 23/7
Number of red cell units transfused 3 (2)
Intramuscular tranexamic acid in trauma patients - 3We analysed the data using the non-linear mixed-effect
modelling programme Monolix 2019R2 http://lixoft.com/
products/monolix/).18 We computed maximum likelihood es-
timators of the parameters without any approximation of the
model (no linearisation) using the stochastic approximation
expectation maximisation algorithm combined to a Markov
chain Monte Carlo procedure. To ensure convergence, the
iteration number was fixed at 2000. For two-compartment
models, the parameters were the first-order i.m. absorptionTable 2 Parameter estimates of the final tranexamic acid population
scaling and to a 44-yr-old patient without signs of shock. BSV, betw
terval; Cl, elimination clearance; F, i.m. bioavailability; ka, appare
compartmental clearance; SoS, clinical sign of shock (0 if no; 1 if ye
peripheral compartment. *F has a logit distribution; therefore, BSV f
Parameter Covariate effect
ka (h
1)
F
Cl (L h1 [70 kg]1)
qBW (BW/70)qBW
qAge (Age/44.2)qAge
qSoS eqSoSSoS
Q (L h1 [70 kg]1)
qBW (BW/70)qBW
Vc (L [70 kg]1)
qBW (BW/70)qBW
qAge (Age/44.2)qAge
qSoS eqSoSSoS
Vp (L [70 kg]1) (BW/70)qBW
qBW
Residual variability proportional N/Aconstant (ka), i.m. bioavailability (F), elimination clearance (Cl),
inter-compartmental clearance (Q), volume of the central
compartment (Vc), and volume of the peripheral compartment
(Vp).
The equations were as follows:
dAM(t)/dt¼ekaxAM(t)
dA1(t)/dt¼kaAM(t)ek10A1(t)ek12A1(t)þk21A2(t)
dA2(t)/dt¼k12A1(t)ek21A2(t)
where AM is the amount of drug in the muscle for the i.m.
route (0 for the i.v. route), A1 and A2 are the amounts of
drug in the compartments, k10¼Cl/Vc, k12¼Q/Vc, and
k21¼Q/Vp.
We investigated different error models (additive, propor-
tional, or combined) to describe residual variabilities (ε), and
the between-subject variabilities (h) were ascribed to an
exponential model. We used the Bayesian information crite-
rion to test different hypotheses about the model, specifically,
covariate effects on parameters, the residual variabilitymodel,
and the structure of the varianceecovariance matrix for the u
parameters. We examined the effect of the following cova-
riates: age, sex, body weight (BW), BMI, GFR, ethnicity, type of
injury, presence of shock, blood lactate, and site of i.m. in-
jection. GFR was calculated according to the Modification of
Diet in Renal Disease equation.19 Parameter estimates were
standardised for a mean standard covariate using a power
function: Pi¼PSTD(COVi/COVSTD)PWR, where PSTD is the stan-
dard value of the parameter, and Pi and COVi are the parameter
and covariate values of the ith individual. The PWR exponents
were estimated from the data. However, for BW, powers of 1
and 0.75 for volumes and clearances, respectively, are
consistent with allometric scaling theory.20 We evaluated the
goodness of fit of eachmodel by visual inspection of individual
concentrationetime courses, observedepredicted (population
and individual) concentration plots, and prediction-corrected
visual predictive checks. Parameter confidence intervalsmodel. Parameters normalised to 70 kg patient using allometric
een-subject variability (h); BW, body weight; CI, confidence in-
nt constant of i.m. absorption; N/A, not applicable; Q, inter-
s); Vc, volume of the central compartment; Vp, volume of the
or F is the BSV of the logit.
Estimate (bootstrap 90% CI) BSV (bootstrap 90% CI)
1.94 (1.45e2.53) 0.52 (0.35e0.68)
0.77 (0.67e0.91) 1$05* (0.52e1.74)
7.1 (5.9e8.5) 0.36 (0.23e0.44)
0.75 (fixed)
e0.428 (e0.702 to e0.170)
e0.642 (e0.833 to e0.403)
11.7 (7.0e16.3)
0.75 (fixed)
16.1 (13.8e19.1) 0.20 (0.10e0.30)
1 (fixed)
0.746 (0.309e0.949)
e0.408 (e0.658 to e0.223)
9.4 (7.8e11.5) 0.31 (0.14e0.45)
1 (fixed)
0.14 (0.11e0.16) N/A
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Fig 1. Tranexamic acid (TXA) concentration with time in 30 patients. Time zero is time of i.v. injection;  denotes observations, green line is
population prediction, dashed line is predicted median, purple line is individual prediction, and blue shaded area is the 90% prediction
interval.
4 - Grassin-Delyle et al.were obtained using non-parametric bootstrapping with the
Rsmlx R package with n¼400 bootstrap replications.
Because we aimed to determine the pharmacokinetics of
i.m. TXA and patients received an i.v. dose before the i.m.
dose, we simulated the concentrationetime profiles for a
single 1 g i.m. dose and for a single 0$5 g i.m. dose. The esti-
mated TXA concentration needed to inhibit fibrinolysis in vitro
is in the range 5e10 mg L1.21 We simulated the time taken to
reach and the time spent above these TXA concentrations. A
protocol was prepared before the analyses, which specified the
statistical analyses to be conducted and is available on ourdata sharing website. This study was registered on EudraCT
(2019-000898-23; registration date: February 5, 2019) and on
ClinicalTrials.gov (NCT03875937; https://clinicaltrials.gov/ct2/
show/NCT03875937; registration date: March 15, 2019).Results
We enrolled 31 patients, but one was withdrawn before
receiving i.m. TXA. Table 1 shows the characteristics of 30
patients who received i.m. TXA. There were 26 males and four
females, with amean age of 50 yr and amean BW of 78 kg. The
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Fig 1. (continued)
Intramuscular tranexamic acid in trauma patients - 5median systolic and diastolic blood pressure were 115 mm Hg
(lower quartile [LQ]¼96; upper quartile [UQ]¼136) and 70 mm
Hg (LQ¼57; UQ¼78), respectively. The median base excess,
serum lactate, and serum creatinine were e4 mM (LQ¼e7;
UQ¼0), 3 mM (LQ¼2; UQ¼6), and 101 mM (LQ¼94; UQ¼127),
respectively. Clinical signs of shock were seen in 18 patients,
and 23 received blood products with a median of 2 units of red
cells transfused (LQ¼1; UQ¼4). Patients with signs of shock
had a lower median systolic blood pressure (97.5 mm Hg;
LQ¼89; UQ¼120 vs 136 mm Hg; LQ¼126; UQ¼151) and a higher
blood lactate (3.6 mM; LQ¼2.5; UQ¼5.6 vs 2.3 mM; LQ¼1.95;
UQ¼3.4) than those without signs of shock. Of the 30 patients
that received i.m. TXA, two had erythema, four had indurationand subcutaneous nodules, and eight had bruising at the in-
jection site. No patients had erythema, induration, or subcu-
taneous nodules beyond the day of injection. There was one
adverse event (pyrexia 2 days after the i.m. injection) and no
serious adverse events.Pharmacokinetic modelling
We obtained 239 serum samples. A two-compartment open
model with first-order absorption and elimination best
described the data. The model building steps are shown in
Supplementary Table 1. Adding the effect of allometrically
scaled BW on Cl, Q, Vc, and Vp; age on Cl and Vc; and clinical
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Fig 2. Diagnostic plots for the final population pharmacokinetic model: prediction-corrected visual predictive check for tranexamic acid
(TXA) concentrations. Blue dots depict measured TXA concentrations. The solid centre lines and the shaded areas stand for the median of
observations and the 95% confidence interval of the predictions in the time intervals.
6 - Grassin-Delyle et al.signs of shock on Cl and Vc improved model performance.
Injection site, blood lactate, and BMI had no effect on i.m.
absorption parameters. In the same way, any influence of
signs of shock on the absorption constant was not supported
by both analysis of variance (P¼0.12) and Wald tests (P¼0.35),
which were performed to evaluate whether this covariate
should be added to the model. Similarly, for F, no covariate
improved model performance. Sex, ethnicity, GFR, and type of
injury had no apparent effect on the pharmacokinetics.
Table 2 shows the population pharmacokinetic estimates, and
Fig. 1 shows the individual TXA concentrationetime profiles.
For a 70 kg patient, aged 44 yr without signs of shock, the
population estimates were 1.94 h1 for i.m. absorption con-
stant (i.e. a 21.4 min absorption half-life), 0.77 for i.m.
bioavailability, 7.1 L h1 for elimination clearance, 11.7 L h1
for inter-compartmental clearance, 16.1 L for the volume of
the central compartment, and 9.4 L for the volume of the pe-
ripheral compartment. For the same patient with signs of
shock, the estimates were 3.7 L h1 for elimination clearance
and 10.7 L for volume of the central compartment.
Between-subject variabilities were estimated for ka, F, Cl,
Vc, and Vp using an exponential model, and the residual
variability was estimated using a proportional error model.
Figure 2 shows the prediction-corrected visual predictive
check plot for the final population pharmacokinetic model
with further diagnostic plots (predicted vs observed concen-
trations; residuals and normalised prediction distribution er-
ror plots and convergence diagnosis) shown in Supplementary
Figs 1e3.Simulations
Figure 3 shows simulated concentrationetime profiles after a
single TXA dose 1 g i.m. After a single TXA dose 1 g i.m., a TXA
concentration of 5 mg L1 would be achieved in about 4 min,
remaining above this level for 10 h. A TXA concentration of 10
mg L1 would be achieved in about 11 min, remaining above
this level for 5.6 h. After a TXA dose 0.5 g i.m., a TXA con-
centration of 5 mg L1 would be achieved in about 10 min,
remaining above this level for 5.8 h. A TXA concentration of 10
mg L1 would be achieved in 22 out of 30 patients in about 20
min, remaining above this level for 2.8 h.Discussion
Intramuscular TXA is well tolerated with only mild and tran-
sient injection site reactions. Intramuscular TXA is rapidly
absorbed, reaching therapeutic concentrations within 15 min.
Blood lactate and signs of shock had no apparent impact on
the rate of absorption. Our results have major implications for
trauma care, particularly in low- andmiddle-income countries
where i.m. TXA could expand access to treatment.Strengths and weaknesses
Our study is the first to examine serum concentrations and
pharmacokinetics of i.m. TXA in bleeding trauma patients. We
obtained data from 30 patients with eight data points per pa-
tient and sampling for up to 12 h. Because TXA is life-saving
and treatment delay reduces the survival benefit, all
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Fig 3. Simulated individual concentrationetime profiles of tranexamic acid (TXA) in 30 patients had they only received a 1 g i.m. dose. Grey
dots () show the real observations after a 1 g i.v. dose, and then a 1 g i.m. dose. The green area shows the concentration range 5 and 10 mg
L1. Signs of shock were taken into account as observed individually for each patient.
Intramuscular tranexamic acid in trauma patients - 7participants received the initial 1 g loading dose intravenously.
However, because the 1 g maintenance infusion is often
interrupted for diagnostic tests (e.g. CT scanning) or surgery
and is sometimes omitted completely, we had no reason to
believe that giving the maintenance dose intramuscularly
would put patients at risk. At the same time, we believe that
the study population is representative of bleeding traumapatients. More than half of the patients had signs of shock, and
the median blood lactate was 3.6 mM.
Prior administration of an i.v. dose allowed calculation of
the absolute bioavailability by the i.m. route, although TXA
losses to haemorrhage may have resulted in some time-
dependant changes in pharmacokinetic parameters and un-
derestimation of bioavailability.22 Although we attempted to
8 - Grassin-Delyle et al.obtain a blood sample 10 min after the i.v. injection, because
patient care was the priority, in many cases this was not
possible. However, we were able to collect samples before the
i.m. dose. With the samples obtained, we built a pharmaco-
kinetic model that provided the necessary pharmacokinetic
parameters. The parameter estimates we obtained are
consistent with those from healthy volunteers and with pop-
ulation models of i.v. TXA in trauma patients.23,24 Although
the effect of age was not detected in previous studies, most
were in different patient populations. The only previous report
in this patient population had a single sampling point per
patient, which makes covariate identification and parameter
estimation difficult.23 Importantly, simulations for patients
between 25 and 80 yr old without signs of shock and receiving
a single i.m. 1 g dose show that concentrations above the
desired threshold are maintained for several hours in all pa-
tients, regardless of age (Supplementary Fig. 4).
The target therapeutic concentrations (5e10 mg L1) were
obtained from a systematic review of in vitro pharmacody-
namic studies. In most of the included studies, high con-
centrations of fibrinolytic activators were added to blood to
speed up fibrinolysis. Because the concentrations used were
higher than those seen in even the most severely injured
patients, results from in vitro studies may have over-
estimated the concentration of TXA needed to inhibit fibri-
nolysis in vivo. Although a combined
pharmacokineticepharmacodynamic study may have been
preferable, collection of data on fibrinolytic markers was not
possible in this emergency situation.Implications
Every year, around five million people worldwide die from
injuries.25 There are one-and-a-half times more injury deaths
than deaths from human immunodeficiency virus, tubercu-
losis, and malaria combined. More than 90% of trauma deaths
are in low- and middle-income countries, with up to 80% of
deaths occurring before hospital arrival.26 Tranexamic acid
safely reduces mortality in bleeding trauma patients. Tra-
nexamic acid is heat stable, inexpensive, and has a long shelf
life. Treatment is highly cost effective in high-, middle-, and
low-income countries.27 However, urgent treatment is essen-
tial. The evidence that i.m. TXA is well tolerated and rapidly
absorbed, even in patients with clinical signs of shock, raises
the possibility that i.m. TXA could be given by trained first
responders, police officers, ambulance drivers, and primary
care nurses, thus greatly expanding timely access to treatment
for patients in low- and middle-income countries. Because
shock had no apparent effect on TXA absorption but reduced
elimination, therapeutic concentrations are achieved slightly
sooner in the most severely injured patients who have the
most to gain from TXA treatment. Prompt treatment would be
facilitated by development of a low-cost, easy-to-use auto-
injector or pre-filled syringes for use by first-aiders. An easy-
to-use TXA auto-injector would also allow wounded soldiers
to administer i.m. TXA to themselves or their colleagues as
soon as possible after wounding to maximise survival.28
The lack of any adverse reactions and rapid absorption
suggest that i.m. TXAmight also have the potential to increase
timely access to treatment for women with PPH. However,
because physiological changes during pregnancy could affect
the distribution and renal elimination of TXA, our results
cannot be generalised to women with PPH, andpharmacokinetic studies in pregnant women are underway
(https://clinicaltrials.gov/ct2/show/NCT04274335).Data sharing
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